The Latest
-
Christopher Furlong / Staff via Getty Images
What the AstraZeneca-BMS rumors reveal about pharma megamergers
Reports of talks were quickly disputed, but the prospect exposed the appeal — and antitrust risks — of combining two pharma giants.
-
Getty Images
FDA allows unique endpoint in rare disease study
Global regulators are allowing the company to use hospitalization as the primary efficacy endpoint in its registration trial for a rare neuromuscular disorder.
-
Permission granted by Merck & Co.
Q&AMerck is pharma’s most patent-exposed company. Now it’s reinventing itself.
Keytruda made Merck an oncology powerhouse, but as the patent cliff looms, its business development leader outlines what’s next.
-
Getty Images
Three potential takeover targets in psychedelics
Lilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.
-
Getty Images
Why pharma’s record-setting M&A streak is so unique
Early-stage candidates, mid-sized companies and of course, Chinese assets, are dominating the dealmaking picture this year.
-
Chip Somodevilla via Getty Images
Trump has another tariff plan to reshore generic drug production. Will it work?
The president’s most recent tariff proposal gives pharma more time to transition its global supply chain and reshore generic drug production.
-
Getty Images
Genetic clues for cell therapy toxicities; Summit’s high-stakes FDA decision
Researchers have pinpointed genes linked to dangerous CAR-T cell therapy side effects, and a predictions market weighs in on Summit’s closely-watched cancer drug.
-
Permission granted by Telix Pharmaceuticals
Q&AHow Telix landed a $2.1 billion radiopharma deal with Regeneron
Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.
-
Permission granted by Caribou Biosciences
BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.
Rather than going head-to-head with approved CAR-T cell therapies, biotechs like Caribou Biosciences are positioning their drugs to fill unique market gaps.
-
Getty Images
Brand-name drug denials are surging, especially for weight-loss
Nearly one-third of prescriptions included in a new study were rejected the first time a patient attempted to fill them.
-
Scott Olson via Getty Images
Kalshi is expanding online betting in drug R&D — unless detractors can stop it
Kalshi sees drug development predictions as a way to improve R&D transparency. Critics say they could create financial incentives around research and undermine public trust.
-
Getty Images
Why 3 secretive biotechs are keeping their science close to the chest
Startups like Altos Labs are keeping pipeline details scarce to protect their ideas from competitors — but some experts say stealth only works for biotechs with deep pockets.
-
Alamy
The FDA was all in on AI. Will that change?
High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.
-
Getty Images
Lilly’s leap into psychedelics; peptides in the spotlight
Eli Lilly is extending its push in neuroscience while the FDA wrestles with controversial peptide drugs.
-
Getty Images
OpinionBiopharma challenges leaders want to tackle
Boosting public trust, delivering genuine breakthroughs and getting trials off the ground remain top-of-mind issues in the industry.
-
Getty Images
What’s in the FDA’s latest batch of rejection letters
A look at two recent CRLs demonstrate the tension and discrepancies between how companies and the agency communicate drug rejections.
-
Andrew Harnik via Getty Images
Why the FDA’s top spot could sit empty for months
Multiple factors could get in the way of confirming a new commissioner before the midterm elections, experts said, leaving the agency’s long-term initiatives in limbo.
-
Permission granted by Eli Lilly
Q&ABeyond weight loss: Lilly aims for leadership in brain science
Lilly’s neuroscience chief discusses the large pharma’s aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer’s.
-
Getty Images
Compounders maintain a firm grip on the GLP-1 market
Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.
-
Michel Lunanga / Stringer via Getty Images
As the Ebola outbreak rages, new treatments are headed into trials. Will they work?
The strain causing the current outbreak has no approved treatments or vaccines but global organizations are rushing to change that.
-
Permission granted by Banyan BioInnovations
Long days, dinners with copious alcohol, and the hunt for emerging assets in China
Why building relationships, navigating cultural nuances and preparing for different deal structures are key to investing in China’s promising drugs.
-
Getty Images
Biotech SpotlightThis startup thinks humans in clinical trials could become a ‘formality’
Deep Origin is attempting to create “virtual humans” that could one day reduce late-stage safety failures and the need for animal testing.
-
Getty Images
How well are AI-discovered drugs faring in the clinic?
Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.
-
Getty Images
Biotech funding gap widens despite rebound in VC investment
Nearly 70 venture-backed biotech startups raised more than $9.1 billion between January and June, but the majority already had drugs in testing.
-
Permission granted by C2N Diagnostics
Biotech SpotlightGalimedix is keeping the amyloid hypothesis alive
The right target but the wrong approach? Why Galimedix’s co-founder believes the company has found an edge in treating Alzheimer’s disease with an amyloid drug.
